Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7980376 | 1.00 | CXCR3 (0.33) | CXCR3ALDH1A1RAB9AALOX15GSTP1 | |
| SCHEMBL68779 | 0.98 | — | — | |
| SCHEMBL7409277 | 0.91 | — | — | |
| SCHEMBL7991290 | 0.85 | ALDH1A1 (0.32) | CXCR3ALDH1A1RAB9A | |
| SCHEMBL7992380 | 0.85 | ALDH1A1 (0.32) | CXCR3ALDH1A1RAB9A | |
| SCHEMBL6589574 | 0.83 | — | — | |
| SCHEMBL4461735 | 0.83 | ALDH1A1 (0.33) | ALDH1A1RAB9A | |
| SCHEMBL791251 | 0.79 | PSMB5 (0.31) | ALDH1A1RAB9A | |
| SCHEMBL2687390 | 0.78 | PIN1 (0.35) | — | |
| SCHEMBL11700246 | 0.78 | PIN1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | claimed |
| JP-2009501198-A | — | — | 2009-01-15 | — | — | JP | claimed |
| CN-101263131-A | Urea glucokinase activators | NOVO NORDISK AS (US) | 2008-09-10 | — | — | CN | claimed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | claimed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | claimed |
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| CN-101263131-B | Urea glucokinase activators | TRANSTECH PHARMA INC | 2013-04-24 | — | — | CN | disclosed |
| EP-2377856-A1 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2011-10-19 | — | — | EP | disclosed |
| EP-2344487-A1 | HEPATITIS C INHIBITOR COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| WO-2010034105-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| CN-101263131-A | Urea glucokinase activators | NOVO NORDISK AS (US) | 2008-09-10 | — | — | CN | disclosed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| US-6277790-B1 | APPLYING PLANTS, SEEDS, SOILS OR ENVIRONMENT | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-21 | — | — | US | disclosed |
| EP-1003741-A1 | SUBSTITUTED HERBICIDE TETRAZOLINONECARBOXYLIC ACID AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007702-A1 | SUBSTITUTED HERBICIDE TETRAZOLINONECARBOXYLIC ACID AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | CXCR3 4668/4885ALDH1A1 1040/4885RAB9A 4155/4885 |
| US-20110077234-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | CXCR3 4668/4885ALDH1A1 1040/4885RAB9A 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.